Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT 4-armed trial	229 people with plaque psoriasis involving at least 10% of body surface	Accidental injury 13% with alefacept (0.025 mg/kg, 0.075 mg/kg, and 0.0150 mg/kg) 5% with placebo Absolute numbers not reported	Significance not assessed
RCT 4-armed trial	229 people with plaque psoriasis involving at least 10% of body surface	Dizziness 9% with alefacept (0.025 mg/kg, 0.075 mg/kg, and 0.0150 mg/kg) 2% with placebo Absolute numbers not reported	Significance not assessed
RCT 4-armed trial	229 people with plaque psoriasis involving at least 10% of body surface	Nausea 6% with alefacept (0.025 mg/kg, 0.075 mg/kg, and 0.0150 mg/kg) 0% with placebo Absolute numbers not reported	Significance not assessed
RCT 4-armed trial	229 people with plaque psoriasis involving at least 10% of body surface area	Cough 5% with alefacept (0.025 mg/kg, 0.075 mg/kg, and 0.0150 mg/kg) 0% with placebo	Significance not assessed
RCT 3-armed trial	507 people with chronic plaque psoriasis involving a mean 21% of body surface area	Headache 19% with alefacept (10 mg and 15 mg) 15% with placebo Absolute numbers not reported	Significance not assessed
RCT 3-armed trial	507 people with chronic plaque psoriasis involving a mean 21% of body surface area	Pruritus 16% with alefacept (10 mg and 15 mg) 10% with placebo Absolute numbers not reported	Significance not assessed
RCT 3-armed trial	507 people with chronic plaque psoriasis involving a mean 21% of body surface area	Infection 16% with alefacept (10 mg and 15 mg) 11% with placebo Absolute numbers not reported	Significance not assessed